Oncology Clinical Trial Case Study for Immunotherapy

This case study details the experience of Fortrea, a biopharmaceutical company, in conducting two Phase III clinical trials focused on immunotherapy for lung and skin cancers. The document outlines the challenges faced during patient recruitment and the strategies implemented to enhance collaboration across various sites and vendors. Key challenges included inconsistent targeting of study participants and restrictive clinical trial eligibility criteria that limited enrollment. Fortrea developed tailored patient mapping and recruitment plans to standardize the approach across institutions. Additionally, a protocol amendment was supported to expand eligibility criteria, allowing more patients to participate. The case study further discusses efforts to increase awareness and engagement among potential participants through educational initiatives targeting surgical centers and involving local medical professionals. Ultimately, Fortrea achieved critical database lock milestones, with the lung cancer treatment receiving U.S. FDA approval, demonstrating effective navigation of complexities in oncology trials.